If our observations in this small series are confirmed in a larger series of leukemia patients, preferably with corresponding proteomics/phosphoproteomics data, proof-of-concept studies with FDA-approved PTKi would be warranted to further evaluate the clinical potential of PTK targeting in KMT2A/MLL-R+ ALL and AML. Here, KMT2A is linked to acute myeloid leukemia.